Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists


Ontology type: sgo:Patent     


Patent Info

DATE

2022-03-15T00:00

AUTHORS

RESCOURIO GWENAELLA , GONZALEZ BUENROSTRO ANA , BROWN SEAN P , LIZARZABURU MIKE , MEDINA JULIO , JABRI SALMAN YOJIRO , SUN DAQING , SIMONOVICH SCOTT PRESTON , YAN XUELEI , LI YIHONG , REW YOSUP

ABSTRACT

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer. More... »

Related SciGraph Publications

  • 2008-12. BCL-2 family antagonists for cancer therapy in NATURE REVIEWS DRUG DISCOVERY
  • 2008-12-16. Mcl-1 is a potential therapeutic target in multiple types of cancer in CELLULAR AND MOLECULAR LIFE SCIENCES
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "name": "RESCOURIO GWENAELLA", 
            "type": "Person"
          }, 
          {
            "name": "GONZALEZ BUENROSTRO ANA", 
            "type": "Person"
          }, 
          {
            "name": "BROWN SEAN P", 
            "type": "Person"
          }, 
          {
            "name": "LIZARZABURU MIKE", 
            "type": "Person"
          }, 
          {
            "name": "MEDINA JULIO", 
            "type": "Person"
          }, 
          {
            "name": "JABRI SALMAN YOJIRO", 
            "type": "Person"
          }, 
          {
            "name": "SUN DAQING", 
            "type": "Person"
          }, 
          {
            "name": "SIMONOVICH SCOTT PRESTON", 
            "type": "Person"
          }, 
          {
            "name": "YAN XUELEI", 
            "type": "Person"
          }, 
          {
            "name": "LI YIHONG", 
            "type": "Person"
          }, 
          {
            "name": "REW YOSUP", 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/nrd2658", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030857223", 
              "https://doi.org/10.1038/nrd2658"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00018-008-8637-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023498818", 
              "https://doi.org/10.1007/s00018-008-8637-6"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2022-03-15T00:00", 
        "description": "

    Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

    ", "endDate": "2039-03-04", "id": "sg:patent.US-11274105-B2", "name": "Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists", "recipient": [ { "id": "http://www.grid.ac/institutes/grid.417886.4", "type": "Organization" } ], "sameAs": [ "https://app.dimensions.ai/details/patent/US-11274105-B2" ], "sdDataset": "patents", "sdDatePublished": "2022-09-02T16:21", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/patent/patent_9.jsonl", "type": "Patent" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.US-11274105-B2'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.US-11274105-B2'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.US-11274105-B2'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.US-11274105-B2'


     

    This table displays all metadata directly associated to this object as RDF triples.

    74 TRIPLES      15 PREDICATES      18 URIs      9 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:patent.US-11274105-B2 schema:about anzsrc-for:06
    2 anzsrc-for:0601
    3 schema:author Nb84cbad6239d48148fcf0df624f1069d
    4 schema:citation sg:pub.10.1007/s00018-008-8637-6
    5 sg:pub.10.1038/nrd2658
    6 schema:datePublished 2022-03-15T00:00
    7 schema:description <p>Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.</p>
    8 schema:endDate 2039-03-04
    9 schema:name Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists
    10 schema:recipient grid-institutes:grid.417886.4
    11 schema:sameAs https://app.dimensions.ai/details/patent/US-11274105-B2
    12 schema:sdDatePublished 2022-09-02T16:21
    13 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    14 schema:sdPublisher N43baca6c19a0440daa13b27d5f11c853
    15 sgo:license sg:explorer/license/
    16 sgo:sdDataset patents
    17 rdf:type sgo:Patent
    18 N2306c84856be442f8bf3c8c0d54d33bb rdf:first N4a3796f487af4e63a52345bf7841b2fe
    19 rdf:rest Nd4a8ebc44ab24db38cfe82c1f9742dcb
    20 N2ad9eea5a0e34ef6ae25e6f513f10fee schema:name YAN XUELEI
    21 rdf:type schema:Person
    22 N2f1f0e531bb7498da91eae79cb6c8f6a schema:name RESCOURIO GWENAELLA
    23 rdf:type schema:Person
    24 N43baca6c19a0440daa13b27d5f11c853 schema:name Springer Nature - SN SciGraph project
    25 rdf:type schema:Organization
    26 N458f2a6b4a5a40419d12fa646cce8d21 schema:name LIZARZABURU MIKE
    27 rdf:type schema:Person
    28 N4a3796f487af4e63a52345bf7841b2fe schema:name SIMONOVICH SCOTT PRESTON
    29 rdf:type schema:Person
    30 N57bf164c24c94f3796f428835a9ed074 schema:name JABRI SALMAN YOJIRO
    31 rdf:type schema:Person
    32 N60b11dabe9e04bc9adaeb8844dbe3c7a rdf:first N57bf164c24c94f3796f428835a9ed074
    33 rdf:rest Nba8430b9ec8e4e4f816dff215ced1206
    34 N69e67e92bfda47249990b6fbe93102d5 schema:name BROWN SEAN P
    35 rdf:type schema:Person
    36 N7d96956959a948219dca10331d98e8cb rdf:first Na8dedcd7a24944feab255803d5d2d22b
    37 rdf:rest rdf:nil
    38 N85af3c2f7d0a40ef99eefdc674923172 schema:name GONZALEZ BUENROSTRO ANA
    39 rdf:type schema:Person
    40 N894b26a181d44b5499bf2ed54a1bc250 rdf:first N458f2a6b4a5a40419d12fa646cce8d21
    41 rdf:rest Nd6d5bb5f0a134e1eb0f73254e57b87f3
    42 Na583cc98277640eeaf587081e12054cd rdf:first Nda9e4931a96744dead9b02f5a654dc76
    43 rdf:rest N7d96956959a948219dca10331d98e8cb
    44 Na8dedcd7a24944feab255803d5d2d22b schema:name REW YOSUP
    45 rdf:type schema:Person
    46 Nb84cbad6239d48148fcf0df624f1069d rdf:first N2f1f0e531bb7498da91eae79cb6c8f6a
    47 rdf:rest Nebc8aaa829084ebfba9ca32482ee2460
    48 Nba8430b9ec8e4e4f816dff215ced1206 rdf:first Nff4088edde4a40aba3a90c20ec2e1a87
    49 rdf:rest N2306c84856be442f8bf3c8c0d54d33bb
    50 Nd37fc0b91fd54fc6b1fdcce1b2989e88 schema:name MEDINA JULIO
    51 rdf:type schema:Person
    52 Nd4a8ebc44ab24db38cfe82c1f9742dcb rdf:first N2ad9eea5a0e34ef6ae25e6f513f10fee
    53 rdf:rest Na583cc98277640eeaf587081e12054cd
    54 Nd6d5bb5f0a134e1eb0f73254e57b87f3 rdf:first Nd37fc0b91fd54fc6b1fdcce1b2989e88
    55 rdf:rest N60b11dabe9e04bc9adaeb8844dbe3c7a
    56 Nda9e4931a96744dead9b02f5a654dc76 schema:name LI YIHONG
    57 rdf:type schema:Person
    58 Nebc8aaa829084ebfba9ca32482ee2460 rdf:first N85af3c2f7d0a40ef99eefdc674923172
    59 rdf:rest Nf3d2581bed564db1859156c6668be760
    60 Nf3d2581bed564db1859156c6668be760 rdf:first N69e67e92bfda47249990b6fbe93102d5
    61 rdf:rest N894b26a181d44b5499bf2ed54a1bc250
    62 Nff4088edde4a40aba3a90c20ec2e1a87 schema:name SUN DAQING
    63 rdf:type schema:Person
    64 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
    65 rdf:type schema:DefinedTerm
    66 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
    67 rdf:type schema:DefinedTerm
    68 sg:pub.10.1007/s00018-008-8637-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023498818
    69 https://doi.org/10.1007/s00018-008-8637-6
    70 rdf:type schema:CreativeWork
    71 sg:pub.10.1038/nrd2658 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030857223
    72 https://doi.org/10.1038/nrd2658
    73 rdf:type schema:CreativeWork
    74 grid-institutes:grid.417886.4 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...